drugset / Trial / NCT03289533
A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the safety, efficacy and PK of avelumab in combination with axitinib as first line treatment in patients with advanced HCC
Timeline
- Start
- 2017-09-08
- Primary completion
- 2019-08-27
- Completion
- 2019-10-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | 10 mg/kg | — |
| Subject | Axitinib | Small molecule | 5 mg | — |